Home » Topics » BioWorld Science

BioWorld Science
RSS

AZD-9574: a selective PARP1 inhibitor suitable for cancer treatment

April 4, 2022

Novel TLR4 murine model to study dermal sensitization by nickel salts

April 4, 2022

Sosei Heptares presents novel GLP-1 receptor antagonist HTL-0033097

April 1, 2022

Humanized mouse model to asses acute toxicity of immune drug treatments

April 1, 2022

New orthotopic xenograft breast cancer murine models developed

April 1, 2022

Novel humanized HIS-BRGS mouse model to evaluate immune-related kidney toxicities

April 1, 2022

Telomere to telomere, the human genome is done

April 1, 2022

RemeGen discloses new anti-c-Met antibody-drug conjugates

April 1, 2022

CNRS and collaborators patent acetylcholinesterase reactivators

April 1, 2022

New NFE2-related factor 2 activators described by Sanofi

April 1, 2022

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 10, 2026.
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...
FENS 2026: Next-gen biologics take on brain disease
BioWorld
Whether by fine-tuning neurotransmitter signaling or silencing disease-associated genes, emerging biologic therapies are reshaping neuroscience drug development,...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
NRF2 activators reported in Vailima Peninsula patent
BioWorld Science
Vailima Peninsula Pty Ltd. has discovered new nuclear factor erythroid 2-related factor 2 (NFE2L2; NRF2) activators potentially useful for the treatment of...